#1 Clinical Trials Search in Europe

Gadobenate Dimeglumine

Gadobenate dimeglumine, also known as MultiHance, is a contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and aid in the diagnosis of various medical conditions. This article examines several clinical trials that have investigated the use of gadobenate dimeglumine in different medical imaging applications, including central nervous system disorders, liver cancer, and cardiovascular diseases.

Table of Contents

What is Gadobenate Dimeglumine?

Gadobenate dimeglumine, also known by the brand name MultiHance, is a type of contrast agent used in magnetic resonance imaging (MRI) scans[1]. It belongs to a class of drugs called gadolinium-based contrast agents (GBCAs). Contrast agents help enhance the visibility of internal body structures during imaging tests like MRIs.

What is Gadobenate Dimeglumine Used For?

Gadobenate dimeglumine is used to improve the visibility of abnormal structures or lesions in various parts of the body during MRI scans. Some of its main uses include:

  • Central nervous system imaging: It helps detect and characterize lesions in the brain and spine[2].
  • Liver imaging: It aids in the detection and characterization of liver lesions, including metastases[3].
  • Cardiovascular imaging: It can be used in MRI scans to assess blood flow and detect heart problems[4].
  • Magnetic resonance angiography (MRA): It enhances the visibility of blood vessels during MRA scans of the carotid, renal, abdominal, and peripheral arteries[5].

How Does Gadobenate Dimeglumine Work?

Gadobenate dimeglumine contains gadolinium, a rare earth metal. When injected into the bloodstream, it circulates through the body and accumulates in abnormal tissues. The gadolinium alters the magnetic properties of nearby water molecules, which enhances the contrast between normal and abnormal tissues on MRI images. This makes it easier for radiologists to detect and characterize lesions or other abnormalities[1].

How is Gadobenate Dimeglumine Administered?

Gadobenate dimeglumine is given as an intravenous (IV) injection, usually just before or during an MRI scan. The dose is typically based on your body weight. For most MRI applications, the standard dose is 0.1 mmol/kg (0.2 mL/kg) body weight[2]. However, the exact dose may vary depending on the specific type of scan and the area of the body being examined.

Effectiveness of Gadobenate Dimeglumine

Clinical studies have shown that gadobenate dimeglumine is highly effective in improving the visibility of abnormalities on MRI scans. For example:

  • In central nervous system imaging, it has been shown to improve the delineation of lesion borders, visualization of internal lesion structure, and overall lesion contrast enhancement[2].
  • In liver imaging, it has demonstrated effectiveness in detecting and characterizing liver lesions, including in patients with colorectal cancer metastases[3].
  • In cardiovascular imaging, it has been used successfully to assess blood flow and detect coronary artery disease[4].

Safety and Side Effects

Gadobenate dimeglumine is generally considered safe when used as directed. However, like all medications, it can cause side effects in some people. Common side effects may include:

  • Headache
  • Nausea
  • Dizziness
  • Injection site reactions (pain, warmth, or coldness)

Serious allergic reactions are rare but can occur. If you experience symptoms such as difficulty breathing, swelling of the face or throat, or severe dizziness, seek immediate medical attention[1].

It’s important to note that in patients with severely impaired kidney function, gadolinium-based contrast agents have been associated with a rare condition called nephrogenic systemic fibrosis. Your doctor will assess your kidney function before administering gadobenate dimeglumine if you have a history of kidney problems[1].

Comparison to Other Contrast Agents

Gadobenate dimeglumine has some unique properties compared to other gadolinium-based contrast agents:

  • It has a higher relaxivity (a measure of how much it enhances contrast) compared to many other GBCAs, which may allow for better image quality or the use of lower doses[5].
  • It has both extracellular and hepatobiliary properties, meaning it can be used for both general MRI applications and specialized liver imaging[3].
  • Some studies have suggested that it may provide better image quality compared to other GBCAs in certain applications, such as brain tumor imaging[2].

However, the choice of contrast agent often depends on the specific clinical situation and the preferences of the radiologist or healthcare facility.

Aspect Details
Primary Uses MRI contrast agent for central nervous system, liver, and cardiovascular imaging
Patient Populations Adults and children, including those under 2 years of age
Dosing Varies by study; ranges from 0.05 mmol/kg to 0.15 mmol/kg
Comparison Studies Evaluated against other contrast agents like gadopentetate dimeglumine and gadopiclenol
Safety Profile Generally well-tolerated; specific safety outcomes reported in individual trials
Imaging Applications CNS disorders, liver cancer, coronary artery disease, atrial fibrillation
Key Outcomes Measured Lesion border delineation, internal morphology visualization, contrast enhancement, diagnostic accuracy
Administration Method Intravenous injection, typically as a single bolus

FAQ

  • What is gadobenate dimeglumine used for in medical imaging? Gadobenate dimeglumine is a contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and improve the visualization of various structures and abnormalities in the body, particularly in the central nervous system, liver, and cardiovascular system.
  • How does gadobenate dimeglumine compare to other contrast agents? Clinical trials have compared gadobenate dimeglumine to other contrast agents, such as gadopentetate dimeglumine and gadopiclenol. These studies aim to determine the relative effectiveness, safety, and optimal dosing of gadobenate dimeglumine in different imaging applications.
  • Is gadobenate dimeglumine safe for use in children? Several clinical trials have investigated the safety and efficacy of gadobenate dimeglumine in pediatric patients, including those under 2 years of age. These studies aim to establish appropriate dosing and assess the contrast agent's performance in imaging central nervous system disorders in children.
  • Can gadobenate dimeglumine be used in patients with atrial fibrillation? A clinical trial has explored the use of gadobenate dimeglumine in combination with regadenoson stress MRI to detect coronary artery disease in patients with atrial fibrillation. This study aims to determine the sensitivity and specificity of this imaging technique in this specific patient population.
  • How is gadobenate dimeglumine being used in liver cancer imaging? A clinical trial has investigated the use of gadobenate dimeglumine-enhanced MRI to assess liver cancer response to transcatheter arterial chemoembolization (TACE). This study aims to determine if the contrast agent can help differentiate between normal liver cells, active tumor, and tumor affected by chemotherapy.

Ongoing Clinical Trials on Gadobenate Dimeglumine

  • Study on the Long-Term Effects of Gadoxetic Acid, Gadoteridol, and Gadobenate Dimeglumine on Motor and Cognitive Functions in Healthy Adults

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy

Glossary

  • Gadobenate dimeglumine: A gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance image quality and improve the visualization of various structures and abnormalities in the body.
  • MultiHance: The brand name for gadobenate dimeglumine, a contrast agent used in MRI scans.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses strong magnetic fields and radio waves to create detailed images of the body's internal structures.
  • Contrast agent: A substance used to improve the visibility of internal body structures in medical imaging techniques such as MRI or CT scans.
  • Central Nervous System (CNS): The part of the nervous system consisting of the brain and spinal cord.
  • Gadolinium: A rare earth element used in contrast agents for MRI due to its magnetic properties.
  • Hepatocellular carcinoma: The most common type of primary liver cancer, originating in the main cell type of the liver.
  • Transcatheter Arterial Chemoembolization (TACE): A minimally invasive procedure used to treat liver cancer by delivering chemotherapy drugs directly to the tumor while blocking its blood supply.
  • Atrial fibrillation: An irregular and often rapid heart rhythm that can increase the risk of stroke and other heart-related complications.
  • Regadenoson: A medication used as a vasodilator in cardiac stress tests to simulate the effects of exercise on the heart.
  • Coronary artery disease: A condition in which the blood vessels supplying the heart become narrowed or blocked, often leading to chest pain, shortness of breath, or heart attacks.
  • Signal-to-Noise Ratio (SNR): A measure used in imaging to compare the level of desired signal to the level of background noise, indicating image quality.
  • Contrast-to-Noise Ratio (CNR): A measure used in imaging to determine how well desired structures can be distinguished from the background, indicating image contrast.
  • Hepatobiliary phase: A stage in liver imaging where contrast agents are taken up by liver cells, allowing for better visualization of liver structure and function.

References

  1. https://clinicaltrials.gov/study/NCT00323310
  2. https://clinicaltrials.gov/study/NCT02291822
  3. https://clinicaltrials.gov/study/NCT04973007
  4. https://clinicaltrials.gov/study/NCT01710254
  5. https://clinicaltrials.gov/study/NCT01260636